Update on the Treatment of Pediatric Tuberculous Meningitis

Regan S. Solomons🔗, PhD, * Ronald van Toorn🔗, PhD, * Fiona V. Cresswell🔗, PhD, †‡§ and James A. Seddon🔗, PhD*¶

Key Words: tuberculous meningitis, pediatric, treatment

At the 2018 high-level United Nations meeting on tuberculosis (TB), treatment targets were set for the 5-year period 2018–2022. These targets included the treatment of 3.5 million children. However, by 2020 only 41% of this target had been achieved with further stasis highly likely due to the havoc wreaked by the COVID-19 pandemic on access to healthcare.1 Tuberculous meningitis (TBM), is considered the most devastating manifestation of TB, with the peak incidence in the vulnerable early childhood age group, coinciding with critical brain development. Early diagnosis in childhood is difficult due to nonspecific clinical features and the paucibacillary nature of the disease complicating cerebrospinal fluid (CSF) mycobacterial confirmation, resulting in delayed diagnosis and treatment. Untreated, TBM is uniformly fatal, and even when treated, the neurological sequelae can be severe. Unfortunately, the evidence to guide treatment is limited. We present a summary of existing pediatric TBM treatment, recent updates, clinical trials which may potentially inform antituberculous dosing regimens, and practical clinical recommendations.

DRUGS, DOSSING REGIMENS AND EVIDENCE

Good CSF penetration is a logical prerequisite for an antituberculous agent to be effective at the site of disease. However, only a handful of antituberculous agents have good CSF penetration. Of the first-line antituberculous drugs, isoniazid and pyrazinamide have the best CSF penetration, while ethambutol and rifampin have poor CSF penetration. Of the first-line antituberculous agents, isoniazid, rifampin and pyrazinamide, given at higher dosages, combined with ethionamide; for 6 months if HIV-negative and for 9 months if HIV-positive. Dosing is shown in Table 1.3 Mortality was lower in the children treated with the intensive 6-month regimen compared to those treated with the standard WHO-recommended 12-month regimen. WHO subsequently decided that the intensive 6-month regimen could be used as an alternative to the 12-month regimen. The rationale for using ethionamide, in preference to ethambutol, in the 6-month intensive regimen is the good CSF penetration compared with ethambutol. A further advantage of ethionamide is that isoniazid mono-resistant katG

The ESPID Reports and Reviews of Pediatric Infectious Diseases series topics, authors and contents are chosen and approved independently by the Editorial Board of ESPID.
TBM is usually overcome when ethionamide and pyrazinamide are used continuously for 6 months. However, hepatotoxicity, gastrointestinal irritability and hypothyroidism are recognized complications of ethionamide. For this reason, fluoroquinolones are being evaluated as the alternative fourth drug.

While the recommendation of the alternative 6-month intensive pediatric TBM regimen is welcomed, the evidence base for childhood TBM treatment regimens remains poor. To address this, two clinical trials are exploring pediatric TBM treatment. TBM-KIDS (NCT02958709) is a recently completed phase II/III trial in which children with TBM were randomized to 1 of 3 regimens for the first 8 weeks of their treatment. The control arm comprised a standard dose of isoniazid, rifampin, pyrazinamide and ethambutol, with the first intervention arm using an increased dosage of rifampin (30 mg/kg) and the second intervention arm using this higher rifampin dose as well as substituting ethambutol with levofloxacin. All arms then completed the same 10 months of a standard continuation phase (isoniazid at 10 mg/kg and rifampin at 15 mg/kg). Pharmacokinetic and safety data will be available immediately. Short Intensive Treatment for Children with Tuberculous Meningitis (SURE) is a randomized trial with a factorial design of enhanced antituberculosis and anti-inflammatory therapy for children with TBM. Children are first randomized to either the standard WHO-recommended 12-month TBM regimen or to an optimized regimen consisting of rifampin (30 mg/kg), isoniazid (20 mg/kg), pyrazinamide (40 mg/kg) and levofloxacin (20 mg/kg) daily for 6 months. Each child is then randomized to receive either aspirin or a placebo for the first 8 weeks of treatment. The study will recruit 400 children until 2023.

NEW INSIGHTS INTO DRUG DOsing STRategies

While both TBM-KIDS and SURE evaluate rifampin at a dose of 30 mg/kg, modeling studies suggest that even higher dosages are required. Given that children generally require higher milligram per kilogram oral dosages to achieve the same serum concentration as adults, it is likely that dosages much greater than 40 mg/kg would be needed in children to achieve the same exposures as seen in adults given 40 mg/kg. A recent pharmacokinetic and safety study using higher dosages of rifampin in children, the Opti-Rif trial, explored short-term dosages of up to 75 mg/kg. Higher dosages were generally well-tolerated, and few adverse events were seen. Much higher dosages of rifampin may soon be used in an attempt to improve outcomes in children with TBM.

HOST-DIRECTED THERAPY

Many of the sequelae seen in TBM can be attributed to a dysregulated host immune response. Effective host-directed therapies (HDT) are therefore likely to be critical in improving survival and clinical outcomes. Currently, the only HDTs that have been shown to reduce TBM mortality are the corticosteroids. However, there is no evidence that corticosteroids reduce morbidity and the mechanism of action for mortality reduction is unclear. Leukotriene A4 (LTA4H) genotype may predict adjunctive corticosteroid responsiveness and once validated the exciting prospect of genotype-directed adjunctive therapy may be possible. Aspirin reduces the risk of new infarctions in adult TBM patients but does not affect mortality, though larger studies powered for survival are needed. Dose uncertainty (low for anti-platelet or high for anti-inflammatory effects) and duration of therapy necessitates further exploration before aspirin can be advocated as standard therapy. One promising HDT approach is to restrict the immunopathology arising from tumor necrosis factor (TNF)-α excess via TNF-α inhibitors, such as thalidomide, anti-TNF-α monoclonal antibodies (infliximab and adalimumab) and the soluble TNF-α receptor fusion protein (etanercept). Low dosage adjunctive thalidomide has been found to be safe and effective in treating tuberculous mass lesions and blindness related to optochiasmatic arachnoiditis. The safety and efficacy of infliximab have also been reported in HIV-uninfected children treated for central nervous system TB with severe paradoxical reactions unresponsive to corticosteroids, and in severe vision-threatening paradoxical TB.

ADULT TRIALS RELEVANT TO CHILDREN

In addition to SURE and TBM-KIDS, there are multiple phase II and III adult TBM trials that have either recently been completed or are ongoing that may inform future childhood TBM treatment. The phase III INTENSE-TBM trial (NCT04145258) has a factorial design, randomizing participants to either a standard WHO regimen or an optimized regimen containing high-dose rifampin and linezolid with second randomization comparing low dose (100 mg) aspirin to placebo. HARVEST (ISRCTN15668391) is a phase III trial evaluating rifampin 35 mg/kg/day compared to the standard WHO regimen. Definitive answers about the impact of

---

**TABLE 1.** Drug Dosing for the 12-month WHO Drug-susceptible Tuberculous meningitis (TBM) Regimen and the 6-month Intensive Regimen with Characteristics of Potential Second-line Antituberculous Drugs for Pediatric TBM

<table>
<thead>
<tr>
<th>Drug</th>
<th>CSF Penetration</th>
<th>12-month Regimen</th>
<th>6-month Intensive Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Dosage and Range (mg/kg)</td>
<td>Maximum Dose (mg)</td>
</tr>
<tr>
<td>Isoniazid (H)</td>
<td>Good</td>
<td>10 (7–15)</td>
<td>300</td>
</tr>
<tr>
<td>Rifampin (R)</td>
<td>Poor (the higher dosage the higher the CSF concentration)</td>
<td>15 (10–20)</td>
<td>600</td>
</tr>
<tr>
<td>Pyrazinamide (Z)</td>
<td>Good</td>
<td>35 (30–40)</td>
<td>2000</td>
</tr>
<tr>
<td>Ethambutol (E)</td>
<td>Poor</td>
<td>20 (15–25)</td>
<td>1000</td>
</tr>
<tr>
<td>Ethionamide (Eto)</td>
<td>Good (&gt;80%)</td>
<td>Not recommended</td>
<td></td>
</tr>
<tr>
<td>Other 2nd line agents</td>
<td></td>
<td>CSF penetration</td>
<td>Dosage (mg/kg)</td>
</tr>
<tr>
<td>Levofloxacin (Lfx)</td>
<td>Good</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Terizidone (Tryd)</td>
<td>Good</td>
<td>15–20</td>
<td></td>
</tr>
<tr>
<td>Linezolid (Lad)</td>
<td>Good</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Delamanid (Dim)/pretomanid (Pa)</td>
<td>Poor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bedaquiline (Bdq)</td>
<td>Poor</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CSF, cerebrospinal fluid.
intensified treatment on survival and functional outcomes are awaited in 2024.

There is a body of emerging compelling evidence about the safety and optimal pharmacokinetics of higher-dose rifampin in TBMs. Since then, the RifT trial (ISRCTN42218549) reported on the safety of high-dose rifampin in people with advanced HIV infection and the resulting plasma and CSF exposures of intravenous administration of 20mg/kg rifampin and oral dosing at 35mg/kg, as compared to standard dosing of 10mg/kg. Both the higher oral dose and intravenous administration led to higher exposures in the CSF with no excess toxicity. ReDEFine (NCT02169882) found that higher dosages of rifampin led to substantially higher plasma and CSF exposures, without increases in adverse events in HIV-negative Indonesians. Results of the recently completed phase II LASER-TBM trial (NCT03927313) which recruited HIV-positive South Africans and evaluated elevated dosages of rifampin and linezolid, with or without high-dose (1000mg) aspirin are awaited.

The ALTER trial (NCT04021121) in Uganda and the SIMPLE trial (NCT03537495) in Indonesia are exploring higher dosages of rifampin and the inclusion of linezolid with a focus on pharmacokinetics and safety.

Finally, in Vietnam, LAST ACT (NCT03100786) explores stratifying dexamethasone by LTA4H genotype in HIV-negative adults. Results of the recently completed phase II LASER-TBM trial (NCT03927313) which recruited HIV-positive South Africans and evaluated elevated dosages of rifampin and linezolid, with or without high-dose (1000mg) aspirin are awaited.

The ALTER trial (NCT04021121) in Uganda and the SIMPLE trial (NCT03537495) in Indonesia are exploring higher dosages of rifampin and the inclusion of linezolid with a focus on pharmacokinetics and safety.

The ALTER trial (NCT04021121) in Uganda and the SIMPLE trial (NCT03537495) in Indonesia are exploring higher dosages of rifampin and the inclusion of linezolid with a focus on pharmacokinetics and safety.

RESEARCH GAPS

In a recent review by Huynh et al.,11 research gaps in pediatric TB treatment were identified. These included (1) unclear optimal antituberculous drug dosing, regimen and duration (short versus 12 months) to effectively treat pediatric TBMs, (2) lack of pediatric pharmacokinetic studies, (3) whether the dosage of isoniazid should be adjusted in fast compared to slow acetylators and (4) which of ethambutol (first-line antituberculous drug), ethionamide or the fluorquinolones (second-line antituberculous drugs) is the best option as the fourth drug in a drug-susceptible TB regimen in addition to rifampin, isoniazid and pyrazinamide. Research gaps were also identified relating to whether host-directed therapy including high-dose aspirin, thalidomide and monoclonal antibodies, such as TNF-alpha inhibitors can reduce neurological morbidity and mortality in pediatric TBMs.

PRACTICAL CLINICAL RECOMMENDATIONS

Early diagnosis and treatment initiation are crucial to improve TBm outcome. The authors’ preference is for the short intensive regimen comprising rifampin, isoniazid, pyrazinamide and ethionamide for 6 months if HIV-negative or 9 months if HIV-positive. Ethionamide-related gastrointestinal irritability can be overcome by giving the ethionamide separately as a night-time dose. Concurrently, prednisolone should be given, at a dose of 2mg/kg for 4 weeks followed by a tapering period of 2 weeks.6

Cerebral salt wasting and syndrome of inappropriate secretion of the antidiuretic hormone are important causes of hyponatremia in TBMs. Irrespective of the cause, the fluid restriction should be avoided, and the management of choice is hypertonic saline (slow infusion with the aim to increase serum sodium by 1 mmol/L/h). Currently, there is insufficient evidence for routine aspirin use, however, if neuroimaging demonstrates cerebral venous sinus thrombosis, arterial ischemic infarction and/or vasculitis, aspirin can be considered. Treatment of tuberculous hydrocephalus depends on the level of CSF obstruction which can be determined using either air-encephalogram or MRI CSF flow studies. Medical therapy, consisting of furosemide 1mg/kg/day and acetazolamide 50–100mg/kg/day, given for 1 month, has been shown to normalize raised intracranial pressure within 7 days of treatment.12 Noncommunicating hydrocephalus should be treated by neurosurgical CSF diversion. In the rare cases of a tuberculosis in a critical area, a tuberculous abscess or ophthoclasmic arachnoiditis, usually seen in paradoxical immune reconstitution inflammatory syndrome, there is evidence for improvement on low dose adjunctive thalidomide or infliximab.

CONCLUSIONS

After years of neglect, substantial research into childhood TBMs has recently completed or is underway. Several studies in adults with TBMs will provide crucial information for the treatment of children and WHO has updated guidance to make optimized treatment an option in all contexts. Despite these advances, TBM remains a devastating condition and much remains unknown in the field of childhood TB therapy.

REFERENCES